Revisiones en Cáncer 00036 / http://dx.doi.org/10.20960/revcancer.00036

Resumen| PDF

Revisión

Tratamiento quirúrgico en cáncer de pulmón

José R. Jarabo, Elena Fernández, Carlos A. Fraile, Verónica Alen, Lidia Sotillo, Verónica Albarrán, Joaquín Calatayud, Ana M. Gómez, Florentino Hernando

Prepublicado: 2023-09-25

Publicado: 2023-11-03

VOLUMEN 37, NÚM. 3, mayo-junio (2023), PAG. 121-132

Logo Descargas Número de descargas: 39161 Logo Visitas Número de visitas: 897 Citas Citas: 0

Compártelo:

El escenario de cáncer de pulmón de célula no pequeña ha cambiado, con nuevos retos como la detección precoz de tumores a través de programas de cribado, abordajes multidisciplinares con nuevos fármacos, una precisa tipificación biomolecular tumoral, el creciente número de pacientes en situación funcional límite que son rescatables para cirugía, y la consecución de resecciones oncológicas completas con abordajes mínimamente invasivos. Los cirujanos torácicos se enfrentan a nódulos pulmonares pequeños sin confirmación citohistológica difíciles de localizar intraoperatoriamente, nuevas peculiaridades técnicas tras tratamientos neoadyuvantes nuevos, pacientes añosos con múltiples comorbilidades y tumores localmente avanzados o metastásicos que se hacen potencialmente resecables tras tratamientos sistémicos. Para ello contamos con nuevas tecnologías como sistemas de asistencia robótica, programas de reconstrucción de imágenes, herramientas para detección y marcaje de nódulos y, especialmente, el entusiasmo de profesionales trabajando para lograr altas tasas de curación y largas supervivencias con máximos niveles de calidad de vida.

Palabras Clave: Cirugía. Cáncer de pulmón. Toracoscopia. Neoadyuvancia. Prehabilitación.

Descargar PDF

Bibliografía
Artículos Relacionados

Expert Consensus Panel, Kidane B, Bott M, Spicer J, Backhus L, Chaft J, et al. The American Association for Thoracic Surgery (AATS) 2023 Expert Consensus Document: Staging and multidisciplinary management of patients with early-stage non-small cell lung cancer. J Thorac Cardiovasc Surg. 9 de junio de 2023;S0022-5223(23)00363-X.

Majem M, Juan O, Insa A, Reguart N, Trigo JM, Carcereny E, et al. SEOM clinical guidelines for the treatment of non-small cell lung cancer (2018). Clin Transl Oncol. enero de 2019;21(1):3-17.

Maconachie R, Mercer T, Navani N, McVeigh G, Guideline Committee. Lung cancer: diagnosis and management: summary of updated NICE guidance. BMJ. 28 de marzo de 2019;364:l1049.
DOI: 10.1136/bmj.l1049

Martini N. Operable lung cancer. CA Cancer J Clin. 1993;43(4):201-14.
DOI: 10.3322/canjclin.43.4.201

Ginsberg RJ, Rubinstein LV. Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Lung Cancer Study Group. Ann Thorac Surg. septiembre de 1995;60(3):615-22; discussion 622-623.
DOI: 10.1016/0003-4975(95)00537-U

Cao C, Chandrakumar D, Gupta S, Yan TD, Tian DH. Could less be more?-A systematic review and meta-analysis of sublobar resections versus lobectomy for non-small cell lung cancer according to patient selection. Lung Cancer. agosto de 2015;89(2):121-32.

Altorki N, Wang X, Kozono D, Watt C, Landrenau R, Wigle D, et al. Lobar or Sublobar Resection for Peripheral Stage IA Non-Small-Cell Lung Cancer. N Engl J Med. 9 de febrero de 2023;388(6):489-98.

Saji H, Okada M, Tsuboi M, Nakajima R, Suzuki K, Aokage K, et al. Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer (JCOG0802/WJOG4607L): a multicentre, open-label, phase 3, randomised, controlled, non-inferiority trial. Lancet. 23 de abril de 2022;399(10335):1607-17.

Chan EG, Chan PG, Mazur SN, Normolle DP, Luketich JD, Landreneau RJ, et al. Outcomes with segmentectomy versus lobectomy in patients with clinical T1cN0M0 non-small cell lung cancer. J Thorac Cardiovasc Surg. mayo de 2021;161(5):1639-1648.e2.
DOI: 10.1016/j.jtcvs.2020.03.041

Detterbeck FC, Mase VJ, Li AX, Kumbasar U, Bade BC, Park HS, et al. A guide for managing patients with stage I NSCLC: deciding between lobectomy, segmentectomy, wedge, SBRT and ablation-part 2: systematic review of evidence regarding resection extent in generally healthy patients. J Thorac Dis. junio de 2022;14(6):2357-86.

Sun WYL, Dang JT, Modasi A, Nasralla A, Switzer NJ, Birch D, et al. Diagnostic accuracy of sentinel lymph node biopsy using indocyanine green in lung cancer: a systematic review and meta-analysis. Gen Thorac Cardiovasc Surg. septiembre de 2020;68(9):905-13.

Kamel MK, Lee B, Harrison SW, Port JL, Altorki NK, Stiles BM. Sublobar resection is comparable to lobectomy for screen-detected lung cancer. J Thorac Cardiovasc Surg. junio de 2022;163(6):1907-15.

Brunelli A. Commentary: Lobectomy should be the exception rather than the rule to resect screen-detected stage I non-small cell lung cancer. J Thorac Cardiovasc Surg. junio de 2022;163(6):1918-9.
DOI: 10.1016/j.jtcvs.2021.08.053

Lee BE, Altorki N. Sub-Lobar Resection: The New Standard of Care for Early-Stage Lung Cancer. Cancers (Basel). 25 de mayo de 2023;15(11):2914.

Lanuti M. Surgical Management of Lung Cancer Involving the Chest Wall. Thorac Surg Clin. mayo de 2017;27(2):195-9.
DOI: 10.1016/j.thorsurg.2017.01.013

Kader S, Watkins A, Servais EL. The oncologic efficacy of extended thoracic resections. J Surg Oncol. febrero de 2023;127(2):288-95.

Rusch VW, Giroux DJ, Kraut MJ, Crowley J, Hazuka M, Johnson D, et al. Induction chemoradiation and surgical resection for non-small cell lung carcinomas of the superior sulcus: Initial results of Southwest Oncology Group Trial 9416 (Intergroup Trial 0160). J Thorac Cardiovasc Surg. marzo de 2001;121(3):472-83.

Dartevelle PG, Mitilian D, Fadel E. Extended surgery for T4 lung cancer: a 30 years’ experience. Gen Thorac Cardiovasc Surg. junio de 2017;65(6):321-8.

Etienne H, Kalt F, Park S, Opitz I. The oncologic efficacy of extended resections for lung cancer. J Surg Oncol. febrero de 2023;127(2):296-307.

Fadel E, Missenard G, Court C, Mercier O, Mussot S, Fabre D, et al. Long-term outcomes of en bloc resection of non-small cell lung cancer invading the thoracic inlet and spine. Ann Thorac Surg. septiembre de 2011;92(3):1024-30; discussion 1030.
DOI: 10.1016/j.athoracsur.2011.04.100

Tankel J, Mouhanna J, Katz A, Fiset PO, Rayes R, Siblini A, et al. The 8th Edition TNM Stage Reclassification of T4 Non-Small Cell Lung Cancer: A Granular Examination of Short and Long-Term Outcomes. Clin Lung Cancer. 12 de abril de 2023;S1525-7304(23)00061-X.
DOI: 10.1016/j.cllc.2023.04.001

Yamanashi K, Menju T, Hamaji M, Tanaka S, Yutaka Y, Yamada Y, et al. Prognostic factors related to postoperative survival in the newly classified clinical T4 lung cancer. Eur J Cardiothorac Surg. 1 de abril de 2020;57(4):754-61.

Gelfand G, Barber E. Recognition and Management of Acute and Late Complications of Pneumonectomy: Clinical Cases and Treatment. Thorac Surg Clin. agosto de 2021;31(3):293-302.

Bribriesco A, Patterson GA. Management of Postpneumonectomy Bronchopleural Fistula: From Thoracoplasty to Transsternal Closure. Thorac Surg Clin. agosto de 2018;28(3):323-35.

Shi W, Zhang W, Sun H, Shao Y. Sleeve lobectomy versus pneumonectomy for non-small cell lung cancer: a meta-analysis. World J Surg Oncol. 11 de diciembre de 2012;10:265.

Robinson LA, Ruckdeschel JC, Wagner H, Stevens CW, American College of Chest Physicians. Treatment of non-small cell lung cancer-stage IIIA: ACCP evidence-based clinical practice guidelines (2nd edition). Chest. septiembre de 2007;132(3 Suppl):243S-265S.
DOI: 10.1378/chest.07-1379

Dunne EG, Fick CN, Jones DR. Mediastinal Staging in Non-Small-Cell Lung Cancer: Saying Goodbye to Mediastinoscopy. J Clin Oncol. 2 de junio de 2023;JCO2300867.
DOI: 10.1200/JCO.23.00867

Non-small cell lung cancer. Version 6. 2015. NCCN Clinical Practice Guidelines in Oncology 2015 [Internet]. NCCN; Disponible en: https://www.nccn.org/store/login/login.aspx?ReturnURL=http://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf

John AO, Ramnath N. Neoadjuvant Versus Adjuvant Systemic Therapy for Early-Stage Non-Small Cell Lung Cancer: The Changing Landscape Due to Immunotherapy. Oncologist. 20 de junio de 2023;oyad125.
DOI: 10.1093/oncolo/oyad125

Provencio M. 12 Progression Free Survival and Overall Survival in NADIM II Study. En: J Thorac Oncol. 2022. p. S2-3.
DOI: 10.1016/j.jtho.2022.07.014

Andrews WG, Louie BE, Castiglioni M, Dhamija A, Farivar AS, Chansky J, et al. Persistent N2 After Induction Is Not a Contraindication to Surgery for Lung Cancer. Ann Thorac Surg. agosto de 2022;114(2):394-400.

Zeng J, Yi B, Chang R, Chen Y, Yu Z, Gao Y. Safety and feasibility of robotic-assisted thoracic surgery after neoadjuvant chemoimmunotherapy in non-small cell lung cancer. Front Oncol. 2023;13:1134713.
DOI: 10.3389/fonc.2023.1134713

Lee JM, Kim AW, Marjanski T, Falcoz PE, Tsuboi M, Wu YL, et al. Important Surgical and Clinical End Points in Neoadjuvant Immunotherapy Trials in Resectable NSCLC. JTO Clin Res Rep. octubre de 2021;2(10):100221.

Ceylan KC, Kaya SO, Samancilar O, Gursoy S, Ucvet A. The effects of neoadjuvant chemotherapy on pulmonary structures: a quantitative analysis. Thorac Cardiovasc Surg. marzo de 2012;60(2):111-5.

Fang M, Hang Q, Jiang H, Cai L, Hu J, Ying H, et al. Efficacy and safety evaluation of neoadjuvant immunotherapy plus chemotherapy for resectable non-small cell lung cancer in real world. Front Oncol. 2022;12:1055610.
DOI: 10.3389/fonc.2022.1055610

Rami-Porta R. The Evolving Concept of Complete Resection in Lung Cancer Surgery. Cancers (Basel). 25 de mayo de 2021;13(11):2583.
DOI: 10.3390/cancers13112583

Augustus E, Zwaenepoel K, Siozopoulou V, Raskin J, Jordaens S, Baggerman G, et al. Prognostic and Predictive Biomarkers in Non-Small Cell Lung Cancer Patients on Immunotherapy-The Role of Liquid Biopsy in Unraveling the Puzzle. Cancers (Basel). 2 de abril de 2021;13(7):1675.

Fleisher LA, Fleischmann KE, Auerbach AD, Barnason SA, Beckman JA, Bozkurt B, et al. 2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 9 de diciembre de 2014;130(24):2215-45.

Connolly JG, Fiasconaro M, Tan KS, Cirelli MA, Jones GD, Caso R, et al. Postinduction therapy pulmonary function retesting is necessary before surgical resection for non-small cell lung cancer. J Thorac Cardiovasc Surg. agosto de 2022;164(2):389-397.e7.
DOI: 10.1016/j.jtcvs.2021.12.030

Shin S, Choi YS, Jung JJ, Im Y, Shin SH, Kang D, et al. Impact of diffusing lung capacity before and after neoadjuvant concurrent chemoradiation on postoperative pulmonary complications among patients with stage IIIA/N2 non-small-cell lung cancer. Respir Res. 10 de enero de 2020;21(1):13.

Tarumi S, Yokomise H, Gotoh M, Kasai Y, Matsuura N, Chang SS, et al. Pulmonary rehabilitation during induction chemoradiotherapy for lung cancer improves pulmonary function. J Thorac Cardiovasc Surg. febrero de 2015;149(2):569-73.

Balagué C, Arroyo A. Prehabilitation: Another step towards the optimization of surgical patients. Cir Esp (Engl Ed). abril de 2020;98(4):175-7.

Burnett C, Bestall JC, Burke S, Morgan E, Murray RL, Greenwood-Wilson S, et al. Prehabilitation and Rehabilitation for Patients with Lung Cancer: A Review of Where we are Today. Clin Oncol (R Coll Radiol). noviembre de 2022;34(11):724-32.

Fraile Olivero CA, Jarabo Sarceda JR, Fernández Martín E, Santos Capa P, Arribas Manzanal PD, Gómez Martínez AM, et al. Implementation of a perioperative care App in elective thoracic surgery. Cir Esp (Engl Ed). abril de 2023;101(4):265-73.

Voorn MJJ, Franssen RFW, Hoogeboom TJ, Van Kampen-van Den Boogaart VEM, Bootsma GP, Bongers BC, et al. Evidence base for exercise prehabilitation suggests favourable outcomes for patients undergoing surgery for non-small cell lung cancer despite being of low therapeutic quality: a systematic review and meta-analysis. European Journal of Surgical Oncology. mayo de 2023;49(5):879-94.

Batchelor TJP, Rasburn NJ, Abdelnour-Berchtold E, Brunelli A, Cerfolio RJ, Gonzalez M, et al. Guidelines for enhanced recovery after lung surgery: recommendations of the Enhanced Recovery After Surgery (ERAS®) Society and the European Society of Thoracic Surgeons (ESTS). Eur J Cardiothorac Surg. 1 de enero de 2019;55(1):91-115.

Lu Y, Yuan Z, Han Y, Zhang Y, Xu R. Summary of best evidence for enhanced recovery after surgery for patients undergoing lung cancer operations. Asia Pac J Oncol Nurs. julio de 2022;9(7):100054.

Qiu C, Dong W, Su B, Liu Q, Du J. The prognostic value of ratio-based lymph node staging in resected non-small-cell lung cancer. J Thorac Oncol. abril de 2013;8(4):429-35.

Darling GE. Current status of mediastinal lymph node dissection versus sampling in non-small cell lung cancer. Thorac Surg Clin. agosto de 2013;23(3):349-56.
DOI: 10.1016/j.thorsurg.2013.05.002

Fujita T, Koyanagi A, Kishimoto K. Treatment outcomes of lobectomy with and without mediastinal lymph node dissection in older patients with clinical N0 non-small cell lung cancer. Asian Cardiovasc Thorac Ann. 8 de junio de 2023;2184923231180778.
DOI: 10.1177/02184923231180778

Chen K, Li Y, Wang J. VATS Versus Open Lobectomy for Stage I or II NSCLC. En: Difficult decisions in thoracic surgery. 3rd ed. Chicago: Springer; 2014. p. 137-52.
DOI: 10.1007/978-1-4471-6404-3_11

Kim D, Woo W, Shin JI, Lee S. The Uncomfortable Truth: Open Thoracotomy versus Minimally Invasive Surgery in Lung Cancer: A Systematic Review and Meta-Analysis. Cancers (Basel). 5 de mayo de 2023;15(9):2630.

Geropoulos G, Esagian SM, Skarentzos K, Ziogas IA, Katsaros I, Kosmidis D, et al. Video-assisted thoracoscopic versus open sleeve lobectomy for non-small cell lung cancer: A systematic review and meta-analysis from six comparative studies. Asian Cardiovasc Thorac Ann. octubre de 2022;30(8):881-93.

Godfrey CM, Marmor HN, Lambright ES, Grogan EL. Minimally Invasive and Sublobar Resections for Lung Cancer. Surg Clin North Am. junio de 2022;102(3):483-92.

Liu S, Li S, Tang Y, Chen R, Qiao G. Minimally invasive surgery vs. open thoracotomy for non-small-cell lung cancer with N2 disease: a systematic review and meta-analysis. Front Med (Lausanne). 2023;10:1152421.
DOI: 10.3389/fmed.2023.1152421

Mattioni G, Palleschi A, Mendogni P, Tosi D. Approaches and outcomes of Robotic-Assisted Thoracic Surgery (RATS) for lung cancer: a narrative review. J Robot Surg. junio de 2023;17(3):797-809.

Savonitto E, Yasufuku K, Wallace AM. Robotic segmentectomy for early-stage lung cancer. Front Surg. 2023;10:1090080.
DOI: 10.3389/fsurg.2023.1090080

Lazar JF, Hwalek AE. A Review of Robotic Thoracic Surgery Adoption and Future Innovations. Thorac Surg Clin. febrero de 2023;33(1):1-10.

Gonzalez-Rivas D, Bosinceanu M, Manolache V, Gallego-Poveda J, Paradela M, Li S, et al. Uniportal fully robotic-assisted sleeve resections: surgical technique and initial experience of 30 cases. Ann Cardiothorac Surg. 31 de enero de 2023;12(1):9-22.

Udelsman BV, Blasberg JD. Advances in Surgical Techniques for Lung Cancer. Hematol Oncol Clin North Am. junio de 2023;37(3):489-97.

Revisión: Cirugía oncológica en la tercera edad. ¿Estamos preparados?

Publicado: 2022-07-26 / http://dx.doi.org/

Resumen | PDF

Revisión: Opciones terapéuticas en gliomas de alto grado del anciano

Publicado: 2022-07-26 / http://dx.doi.org/

Resumen | PDF

Revisión: Cáncer ginecológico en la anciana

Publicado: 2022-07-28 / http://dx.doi.org/

Resumen | PDF

Revisión: Cáncer de pulmón en el paciente anciano

Publicado: 2022-07-28 / http://dx.doi.org/

Resumen | PDF

Revisión: Cirugía en el cáncer de estómago

Publicado: 2022-07-28 / http://dx.doi.org/

Resumen | PDF